Pompey, France, 26 June 2013 - Novasep, a leading provider of purificationbased manufacturing solutions for life sciences molecules, today announces the appointment of Michel Spagnol as President and CEO of the company, effective from 25 June 2013. He will succeed Patrick Glaser, who after three years at Novasep in France, has decided to return to the USA. Michel Spagnol joins Novasep from Shasun, where he was President and Chief Technology Officer. He is a proven business leader with core expertise in leading contract manufacturing of active pharmaceutical ingredients and, more broadly, strong experience in using and developing innovative technologies to address needs of customers in fine chemicals and life sciences fields. Prior to Shasun Michel Spagnol spent his career at Rhodia in Lyon and Cranbury (NJ, USA) where he progressed first in technical R&D leadership roles and subsequently transitioned to business development as a Sales and Marketing Vice President of Rhodia Pharma Solutions.
Pompey, France and Leverkusen, Germany, June 4, 2013 - Novasep, a leading supplier of manufacturing solutions to the life sciences industry, announces it has strengthened its position in the fine chemicals marketplace with the appointment of Udo Steinhauer as fine chemicals market director within the synthesis business unit of Novasep.
Novasep reclassifies reagent and informs market about new safety measures required.
State of the Art Processes in Large Scale Production of Pharmaceuticals and Fine Chemicals.
Sius(TM) TFF skid to be showcased at the Disposable Solutions for Biomanufacturing tradeshow in Brussels on February 19-20, 2013.
New plant on its Mourenx, France site to produce a large volume commercial API.
Pompey, France, 2nd October 2012 - Novasep, a leading provider of purification-based manufacturing solutions for life science molecules, today announces the appointment of Roger-Marc Nicoud, founder and CEO, as Non-Executive Chairman of the Board, effective on October 1st, 2012.
Pompey, France, July 19, 2012 - Novasep, a leading supplier of manufacturing solutions to the life sciences industries, announces today a three million euro investment to expand its Highly Potent API (HPAPI) manufacturing capabilities at its Le Mans (France) facility. The expansion has been designed to allow Novasep to serve the increased demand for manufacturing of novel anti-cancer therapies.
Pompey, France, April 23, 2011 – Novasep, a leading supplier of purification and production solutions for the life sciences industry, announces two new managerial appointments. Jean-Claude Romain becomes the group’s Corporate Quality Director and a member of Novasep’s executive committee, while Alain Lamproye joins Novasep Process, the company’s biomolecules division, as Director of Novasep Belgium and becomes a member of Novasep Process’s management committee.
Cerenis Therapeutics to present manufacturing data for this biopharmaceutical against atherosclerotic cardiovascular disease at BioProcess International (BPI) Conference in Prague (Czech Republic), April 18, 2012.